| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Combination therapy of Oncolytic vaccinia virus JX-594 and immunosuppression has possibilities to overcome the treatment-resistant progressive cancer. Recently, it is known that cancer stem cells (CSCs) cause the treatment resistance. CSCs are suitable therapeutic targets for overcoming the treatment-resistance. We decided to research the efficacy of combination therapy of JX-594 and immunosuppression to hepatocellular carcinoma CSCs. However, to incubate CSCs stably was difficult, so that we have to establish the stable CSC's incubation method at first. We found that CD13 positive cells in hepatocellular carcinoma cell line, Li-7, had CSC features and those cells could be maintained stably by mTeSR1 medium. This result is useful to develop the new treatment for CSCs. We will apply this incubation method to research the efficacy of combination therapy of JX-594 and immunosuppression to treatment-resistant hepatocellular carcinoma.
|
